Standard BioTools, Inc. (LAB) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$0.62

From 52W high−61.71%

Volume413369.00

Market cap$252.55M

P/E (TTM)—

P/S (TTM)3.0x

Div yield—

Key dataOct 19, 2026

Open

$0.62

From 52W high

−61.71%

Volume

413369.00

Market cap

$252.55M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

2.1x

P/E (TTM)

—

RSI (14)

40.5

MomentumView details →

1D Return

+2.27%

YTD Return

−49.75%

SummaryUpdated Jun 1, 2026

Standard BioTools Inc. (NASDAQ:LAB) is a life sciences tools company that was founded in 1999 as Fluidigm Corporation and rebranded to its current name in April 2022. The company designs, manufactures, and markets specialized scientific instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. Standard BioTools underwent a significant transformation in January 2024 when it merged with SomaLogic, a proteomics company, creating a diversified platform focused on multi-omics research tools. The company is headquartered in South San Francisco, California, and serves academic research institutions, pharmaceutical companies, biotechnology firms, and clinical laboratories globally.

Ask drillr about Standard BioTools, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

2.1x

EV/Sales

−2.3x

P/S (TTM)

3.0x

P/B (TTM)

0.5x

ProfitabilityView details →

Gross Margin

49.14%

Net Margin

−103.29%

EBITDA Margin

−110.38%

ROE (TTM)

−16.18%

ROA (TTM)

−13.93%

Asset Turnover

0.13x

GrowthView details →

Revenue YoY

−36.71%

EPS YoY

+27.97%

FCF YoY

+21.69%

Revenue CAGR 3Y

−4.49%

EPS CAGR 3Y

+61.54%

EBITDA YoY

−13.81%

MomentumView details →

1D Return

+2.27%

YTD Return

−49.75%

1Y Return

−49.75%

RSI (14)

40.5

vs 50D SMA

−7.91%

vs 200D SMA

−32.46%

Capital & dividendView details →

Debt/Equity

0.05x

Current Ratio

9.10x

Quick Ratio

8.80x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.07

EPS Surprise

−449.02%

Beats (12Q)

5/12

Next Q EPS Est

−$0.02

Avg Surprise (4Q)

−30.11%

Rev Surprise

−3.37%

Financials snapshotView financials →

Revenue (TTM)

84.60M

Net Income (TTM)

−87.38M

Op. CF (TTM)

−80.31M

Next earningsNov 3, 2026 →

Latest newsMore news →

Standard BioTools Inc. entered into a definitive agreement to sell its Microfluidics business to healthcare-focused investment firm ARCHIMED.14d ago

Standard BioTools entered into a new purchase agreement with Element Biosystems, a subsidiary of GMT Venture, to sell its mass cytometry business after deeming GMT Venture's unsolicited acquisition proposal superior.19d ago

Similar companies

Treace Medical Concepts, Inc.TMCI Movano Inc.MOVE Anika Therapeutics, Inc.ANIK ClearPoint Neuro, Inc.CLPT Rainmed Medical Limited02297.HK TriSalus Life Sciences, Inc.TLSI Find similar companies →

Latest newsMore news →

Standard BioTools Inc. entered into a definitive agreement to sell its Microfluidics business to healthcare-focused investment firm ARCHIMED.14d ago Standard BioTools entered into a new purchase agreement with Element Biosystems, a subsidiary of GMT Venture, to sell its mass cytometry business after deeming GMT Venture's unsolicited acquisition proposal superior.19d ago Standard BioTools Inc. reported Q2 2026 financial results with revenue declining 7.6% year over year to $20.1 million and net loss widening to $26.8 million.55d ago